Abstract
The occurrence of metabolic syndrome is a risk factor for developing cardiovascular disease. Moreover, the size oflow-density lipoprotein (LDL) particles, and liver dysfunction identified as nonalcoholic fatty liver disease (NAFLD) both represent important biomarkers for the development of cardiometabolic risk in patients with metabolic syndrome. Patients being treated with bergamot polyphenolic fraction show significant reductions in fasting plasma glucose, serum LDL cholesterol and triglycerides along with an increase of high-density lipoprotein cholesterol level. This effect is accompanied in ultrasonography examination by significant reduction NAFLD.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.